How big is the congestive heart failure drug market | Growth & Forecast

Q: What is the current size of the congestive heart failure drug market?

The congestive heart failure drug market was valued at USD 9.4 billion in 2024 and is projected to reach USD 24.5 billion by 2031.

Q: What is the growth rate of the congestive heart failure drug market?

The market is anticipated to grow at a CAGR of 10.6% between 2025 and 2031.

Q: Which components contribute the most to the congestive heart failure drug market?

ACE inhibitors, beta-blockers, ARNIs, diuretics, and SGLT2 inhibitors are major contributors.

Q: What is driving demand in the congestive heart failure drug market?

Demand is driven by aging populations, rising disease burden, and introduction of effective combination therapies.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA5940

Publication Date: Jul 2025

How big is the Congestive Heart Failure Drug Market?

According to 6Wresearch internal database and industry insights, the Global congestive heart failure drugs market was valued at approximately USD 12.4 Billion in 2024 and is expected to reach USD 19.1 Billion by 2031, growing at a compound annual growth rate of 6.00% during the forecast period (2025-2031).

View Main Report

Schedule Analyst Call

The market is expanding steadily due to the rising global prevalence of heart failure, advancements in drug therapies, and supportive healthcare infrastructure in both developed and emerging economies.

Key Growth Drivers of the Congestive Heart Failure Drug Market

Increasing prevalence of cardiovascular diseases and aging population
Growing adoption of advanced drugs including ARNIs and SGLT2 inhibitors
Improved diagnosis and awareness regarding heart health
Expansion of healthcare access in emerging regions
Rising number of clinical trials and product approvals

Congestive Heart Failure Drug Market Trends

The congestive heart failure drug market is witnessing rapid innovation with the entry of new drug classes such as ARNIs and SGLT2 inhibitors that improve survival and reduce hospitalization. Traditional treatments like ACE inhibitors, beta-blockers, and diuretics remain widely used, while combination therapies are gaining popularity. Oral drugs continue to dominate due to patient convenience, while hospital-administered drugs serve critical care needs. Pharma companies are focusing on expanding indications and securing global approvals. Increasing partnerships between public institutions and private drug developers are also enhancing R&D capabilities. North America leads the market due to strong healthcare systems, while Asia-Pacific is expected to grow at a fast pace due to rising diagnosis and treatment accessibility.

Emerging Developments in the Congestive Heart Failure Drug Market

The congestive heart failure drug market is evolving with the development of novel drug delivery systems, gene therapies, and combination therapies. Companies are focusing on AI-driven research, real-world evidence integration, and patient monitoring to improve treatment outcomes. The introduction of biosimilars and generic versions of key drugs is expected to widen access. Telemedicine and remote cardiac care are also supporting early intervention and medication adherence. Overall, innovation is driving a shift toward more personalized and effective heart failure management options.